ClinicalTrials.gg
RecruitingNCT07461610Updated May 18, 2026

Stool Analysis After Sleeve Gastrectomy vs Gastric Bypass

An observational study in Morbid Obesity, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Cairo University · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Obesity, Morbid with a site in Egypt — 12 open to participants now, 16 under way, none of them phase 3. Obesity, Morbid · Egypt.

Started
2026
with 9 others
Observational
7 of 76
4 open now
Primary completion
2026-11
later than 6 of 15 live
Registered
65th of 76
by date
Lead sponsor
5 of 76
Cairo University

Among the 76 studies in Obesity, Morbid with a site in Egypt, this one is one of 10 that started in 2026, is one of 7 observational ones, reaches primary completion later than 6 of the 15 other live ones, and was the 65th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

12 of the 76 studies in Obesity, Morbid with a site in Egypt are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Obesity, Morbid with a site in Egypt, or all of them as a file.
02

Study summary

The goal of this observational study is to learn whether routine stool tests can detect changes in gut function 6 months after two common types of weight loss surgery: sleeve gastrectomy and gastric bypass (including mini gastric bypass and Roux-en-Y gastric bypass). The main questions it aims to answer are:

Do stool tests show more signs of undigested food or carbohydrate malabsorption after gastric bypass compared to sleeve gastrectomy?

Do signs of gut inflammation in stool (like fecal calprotectin) decrease after surgery, and does this relate to improvements in blood sugar and weight loss?

Can simple stool test results at 6 months predict how much weight a person loses or how well their diabetes improves?

Researchers will compare stool test results between the two surgery groups (sleeve gastrectomy vs. gastric bypass) to see if the type of surgery leads to different changes in gut health.

Participants will:

Provide a stool sample before surgery and again 6 months after surgery

Provide a blood sample at the same time points to measure weight, blood sugar, and cholesterol

Undergo their planned weight loss surgery as part of their regular medical care

Read the detailed description

Background:

Obesity is a global pandemic with rising incidence, contributing significantly to morbidity, mortality, and healthcare costs worldwide. Bariatric surgery, particularly sleeve gastrectomy (SG) and gastric bypass procedures (including Mini Gastric Bypass [MGB] and Roux-en-Y Gastric Bypass [RYGB]), remains the most effective and durable treatment for morbid obesity, achieving sustained weight loss and remission of metabolic comorbidities such as type 2 diabetes.

The gastrointestinal tract, particularly the gut microbiome, has emerged as a key metabolic regulator. Obesity is associated with dysbiosis-reduced microbial diversity and altered predominance of bacterial phyla-which contributes to systemic inflammation, insulin resistance, and metabolic syndrome. Bariatric surgery induces profound and durable changes in the gut environment, including alterations in gastric emptying, intestinal transit time, bile acid signaling, and the composition of the gut microbiota.

However, advanced microbiome sequencing is expensive, time-consuming, and not readily available in many clinical settings. Routine stool analysis, by contrast, is a simple, inexpensive, and universally available test that can provide valuable preliminary data on gut health. Parameters such as stool pH, the presence of leukocytes, undigested food particles, and quantitative markers like fecal calprotectin and reducing substances can offer indirect evidence of maldigestion, mucosal inflammation, and microbial activity.

Objective:

The primary objective is to compare changes in routine stool parameters (physical examination, microscopic examination, undigested food particles, fecal calprotectin, and reducing substances) from baseline to 6 months postoperatively between patients undergoing SG and those undergoing Gastric Bypass (MGB or RYGB).

Secondary objectives include: correlating postoperative changes in stool parameters with clinical outcomes (%TWL, diabetes remission, changes in HbA1c and lipid profile); comparing the prevalence of specific stool findings between groups; evaluating whether baseline stool parameters can predict postoperative outcomes; and assessing the utility of routine stool analysis as a simple, low-cost tool for monitoring gut health after bariatric surgery.

Methods:

This is a prospective, two-arm, observational cohort study conducted at the Department of General Surgery, Kasr Al-Ainy University Hospitals, Cairo, Egypt. The study period is from March 2026 to December 2026.

Study Timeline and Data Collection:

Patients will be assessed at two predefined time points:

T0 (Baseline): 1-2 weeks preoperatively - informed consent, demographic data, medical history, anthropometric measurements, blood samples, stool sample

T1 (6 months): 6 months ± 2 weeks postoperatively - anthropometric measurements, blood samples, stool sample, assessment of comorbidities, final outcomes

Clinical and Anthropometric Measurements:

Body weight (kg) and height (m) for BMI calculation (kg/m²)

Percentage total weight loss (%TWL) at 6 months = [(initial weight - 6-month weight) / initial weight] × 100

Presence and status of comorbidities (diabetes, hypertension, dyslipidemia)

Diabetes remission defined as HbA1c \< 6.5% off all antidiabetic medications at 6 months

A total of 46 patients with morbid obesity (BMI ≥40 or ≥35 kg/m² with comorbidities) scheduled for primary laparoscopic bariatric surgery will be enrolled and allocated into two groups: Group A (SG, n=23) and Group B (Gastric Bypass [MGB or RYGB], n=23). The type of gastric bypass (MGB vs. RYGB) will be determined by the surgical team based on patient anatomy, comorbidities, and surgeon preference, reflecting real-world clinical practice.

Blood Sampling and Biochemical Analysis:

After an overnight fast (8-12 hours), venous blood will be collected at both time points for:

  • Fasting plasma glucose (mg/dL)
  • Glycated hemoglobin (HbA1c %)
  • Lipid profile: total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides (mg/dL)
  • High-sensitivity C-reactive protein (hs-CRP) (mg/L) as a marker of systemic inflammation

Stool Sample Collection and Analysis:

Patients will be provided with a sterile, leak-proof stool collection container and written instructions. They will collect a fresh morning stool sample at home. Samples should be transported to the hospital laboratory within 2 hours of collection. If immediate transport is not possible, samples should be refrigerated (4°C) and transported within 12 hours.

Stool analysis parameters include:

Physical Examination: Color, consistency, odor, mucus, pH

Microscopic Examination: White Blood Cells (WBCs), Red Blood Cells (RBCs), trophozoites, cysts, ova, larva, flagellates, ciliate

Undigested Food Particles: Meat fibers, vegetable particles, starch granules, fat globules

Quantitative Tests: Fecal calprotectin (ELISA), Reducing substances (Clinitest tablets)

03

Conditions studied

  • Morbid Obesity

Browse trials for

Keywords

  • Bariatric Surgery
  • Stool Analysis
  • Fecal Calprotectin
  • Reducing Substances
  • Maldigestion
  • Gut Microbiota
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with morbid obesity scheduled for primary bariatric surgery at Kasr Al-Ainy University Hospitals, Cairo, Egypt.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients aged 18 to 60 years
  • (BMI) ≥ 40 kg/m², OR BMI ≥ 35 kg/m² with at least one obesity-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, osteoarthritis, obstructive sleep apnea)
  • Patients scheduled for primary laparoscopic bariatric surgery (either SG or Gastric Bypass [MGB or RYGB]) at Kasr Al-Ainy University Hospitals
  • Provision of written

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years or > 60 years
  • Previous bariatric surgery or major gastrointestinal surgery (gastric, intestinal, or colorectal resection)
  • Chronic kidney disease ( \< 60 mL/min/1.73m²) or previous renal transplant
  • Chronic liver disease (cirrhosis, chronic hepatitis) or liver failure
  • Chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis), celiac disease, or chronic pancreatitis
  • Active or history of chemotherapy/radiotherapy in the past 5 years
  • Pregnancy or breastfeeding
  • Chronic alcohol abuse or substance abuse
  • Use of antibiotics, probiotics, or prebiotics within 4 weeks prior to stool sample collection (to avoid confounding effects on gut flora)
  • Acute gastrointestinal infection at the time of sample collection
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Sleeve Gastrectomy (SG)

    Patients undergoing primary laparoscopic sleeve gastrectomy as treatment for morbid obesity. This group serves as the restrictive procedure comparator.

    Procedure: Laparoscopic Sleeve Gastrectomy

  • Gastric Bypass (MGB/RYGB)

    Patients undergoing primary laparoscopic gastric bypass, including both Mini Gastric Bypass (MGB) and Roux-en-Y Gastric Bypass (RYGB), as treatment for morbid obesity. This group serves as the diversionary procedure comparator.

    Procedure: Mini Gastric Bypass · Procedure: Roux-en-Y Gastric Bypass

Interventions

  • ProcedureLaparoscopic Sleeve Gastrectomy

    Laparoscopic sleeve gastrectomy performed using a standard technique with a 36-Fr bougie, transecting the stomach starting 4-6 cm from the pylorus, excising the entire greater curvature and fundus. The staple line is inspected for hemostasis and leakage.

  • ProcedureMini Gastric Bypass

    Laparoscopic mini gastric bypass performed using a standard technique with a long gastric tube created from the angle of His to the antrum, and a loop gastrojejunostomy with a biliopancreatic limb of 200 cm.

  • ProcedureRoux-en-Y Gastric Bypass

    Laparoscopic Roux-en-Y gastric bypass performed using a standard antecolic, antegastric technique. A small 30-mL gastric pouch is created. The biliopancreatic limb is 70-150 cm, and the alimentary (Roux) limb is 100-150 cm. Jejunojejunostomy is performed to restore continuity.

06

What researchers measure

Primary outcomes

  1. Change in Stool pH

    Change in stool pH measured by pH indicator strip from preoperative baseline to 6 months after surgery. Comparison will be made between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

  2. Change in Fecal Calprotectin Level

    Change in fecal calprotectin concentration (μg/g) measured by ELISA from preoperative baseline to 6 months after surgery. Comparison will be made between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

  3. Presence of Undigested Food Particles

    Presence or absence of undigested meat fibers and vegetable particles on microscopic examination at 6 months after surgery. Comparison of prevalence between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

  4. Presence of Reducing Substances

    Presence or absence of reducing substances (indicating carbohydrate malabsorption) measured by Clinitest tablets at 6 months after surgery. Comparison of prevalence between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

  5. Change in Stool White Blood Cell Count

    Change in white blood cell count (cells per high-power field) on microscopic examination from preoperative baseline to 6 months after surgery. Comparison will be made between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

  6. Change in Stool Red Blood Cell Count

    Change in red blood cell count (cells per high-power field) on microscopic examination from preoperative baseline to 6 months after surgery. Presence of RBCs may indicate mucosal irritation at staple lines or altered barrier function. Comparison will be made between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

Secondary outcomes

  1. Percentage Total Weight Loss (%TWL)

    Percentage total weight loss calculated as \[(initial weight - 6-month weight) / initial weight\] × 100. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: 6 months postoperatively

  2. Diabetes Remission Rate

    Proportion of patients with type 2 diabetes at baseline who achieve remission, defined as HbA1c \< 6.5% off all antidiabetic medications at 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: 6 months postoperatively

  3. Change in Fasting Plasma Glucose

    Change in fasting plasma glucose (mg/dL) from preoperative baseline to 6 months after surgery

    Time frame: At Baseline and at 6 months postoperatively

  4. Change in HbA1c

    Change in glycated hemoglobin (HbA1c %) from preoperative baseline to 6 months after surgery.

    Time frame: At Baseline and at 6 months postoperatively

  5. Change in Lipid Profile

    Changes in total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides (mg/dL) from preoperative baseline to 6 months after surgery.

    Time frame: At Baseline and at 6 months postoperatively

  6. Change in High-Sensitivity C-Reactive Protein (hs-CRP)

    Change in hs-CRP (mg/L) from preoperative baseline to 6 months after surgery as a marker of systemic inflammation.

    Time frame: At Baseline and at 6 months postoperatively

  7. Correlation Between Stool Parameters and Clinical Outcomes

    Correlation between changes in stool parameters (WBC count, RBC count, pH, fecal calprotectin, reducing substances, undigested food particles, mucus, trophozoites, cysts, ova, larva, flagellates, ciliates) and clinical outcomes (%TWL, change in HbA1c) using Spearman's rank correlation coefficient.

    Time frame: 6 months postoperatively

  8. Prevalence of Elevated Fecal Calprotectin

    Prevalence of elevated fecal calprotectin (\>50 μg/g) in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

  9. Prevalence of Positive Reducing Substances

    Prevalence of positive reducing substances (indicating carbohydrate malabsorption) in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

  10. Prevalence of Mucus in Stool

    Prevalence of visible mucus on physical examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

  11. Prevalence of Elevated White Blood Cells in Stool

    Prevalence of elevated white blood cells (\>10 per high-power field) on microscopic examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

  12. Prevalence of Elevated Red Blood Cells in Stool

    Prevalence of elevated red blood cells (\>5 per high-power field) on microscopic examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

  13. Prevalence of Trophozoites in Stool

    Prevalence of trophozoites (any) on microscopic examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

  14. Prevalence of Cysts in Stool

    Prevalence of cysts (any) on microscopic examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

  15. Prevalence of Ova in Stool

    Prevalence of ova (any) on microscopic examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

  16. Prevalence of Larva in Stool

    Prevalence of larva (any) on microscopic examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

  17. Prevalence of Flagellates in Stool

    Prevalence of flagellates (e.g., Giardia) on microscopic examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

  18. Prevalence of Ciliates in Stool

    Prevalence of ciliates (e.g., Balantidium coli) on microscopic examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.

    Time frame: At Baseline and at 6 months postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2026, 7 months after the start.

Of 138 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 7 months is below that.

Counting every sponsor, half of 139 studies reached it within 46 months; a quarter within 16 and three quarters within 132.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 10, 2026
StartActual
Apr 5, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07461610
Lead sponsor
Cairo University
Responsible party
Ahmed Eid Ali Ahmed Aziz (Lecturer, Cairo University) — Principal investigator
First posted
Mar 10, 2026
Start date
Apr 5, 2026
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 18, 2026

Study contacts

Ahmed Eid Aziz, Lecturer
Contact
Ahmed-eid@kasralainy.edu.eg
+201127060844

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion